The understanding of genetic alterations (such as in KRAS and BRAF mutations) in metastatic CRC (mCRC) via the use of gene profiling can be a catch point in explaining the gene's resistance to antiepidermal growth factor receptor (EGFR) antibody management [11] and as a prognostic predictor in arresting the progress of CRC [12] [8, 13]. The gene discussed is BRAF; the disease is colorectal carcinoma.